INTRODUCTION
============

Despite great advancements in genomics research, DNA microarrays are still of limited applicability as diagnostic tests, in part because proteins, not genes, are the ultimate effectors of a biological process. Proteins are often expressed at concentrations and varied structural forms having modifications that cannot be predicted from mRNA analysis. There is a great deal of interest in proteomics-based approaches that enable profiling the abundance of proteins, or investigation of protein-protein and protein-drug interactions. The concept of a protein microarray or biochip is attractive for rapid, high-throughput proteomics studies that utilize available sample volumes \[[@B1], [@B2], [@B3], [@B4]\]. Proteins that are present in abnormal concentrations (increased or decreased) in a disease state could be identified and validated as disease markers. Proteomics pattern analysis based on a multiplexed list of biomarkers may well make possible the diagnosis of certain diseases that do not have either effective screening options or biomarkers already detected by conventional immunoassays \[[@B5]\]. Identification of such disease markers will provide valuable information for detection, classification, and prognosis of diseases, as well as targets for treatment outcomes. High-throughput protein chips require arraying a wide range of probes that specifically recognize a single protein in complex mixtures such as serum, plasma, and other biological specimens. These probes are most frequently antibodies or antibody mimics \[[@B3], [@B4], [@B6], [@B7]\].

Given the immense promise of proteomics technologies, there are still limitations that need to be overcome, such as lack of sensitivity and enhanced information about the target. Because there is no PCR equivalent available to amplify proteins, the identification of low-abundance proteins may often be difficult or impossible, and important biomarker information could thus be lost. Rolling-circle amplification (RCA) is a unique signal amplification technology \[[@B8]\] that permits detection of multiple proteins with a broad dynamic range on protein microarrays \[[@B4], [@B9]\]. In this paper, we describe the development of RCA-based highly multiplexed and sensitive protein microarray immunoassays for detecting 150 proteins in an ELISA format. Application to human serum and plasma samples has established that the rolling-circle amplified protein microarray is a powerful tool for the profiling of expressed proteins in biological specimens.

MATERIAL AND METHODS
====================

*Preparation of microarrays.* Glass slides were prepared and silanized according to procedures previously described \[[@B10]\]. Antibodies (R&D Systems, Minneapolis, Minn; Pharmingen, San Diego, Calif; BioSource International, Camarillo, Calif) were diluted to 0.5 mg/mL in PBS containing 0.05 mg/mL BSA, and 375 pL of each was spotted in quadruplicate onto the slides using a BioChip Arrayer (Packard BioSciences, Downers Grove, Ill). Each spot has a diameter of approximately 180 *μ*m with a center-to-center spacing of 270 *μ*m. Each slide was divided by a teflon mask into 16 subarrays, each with a diameter of 0.65 cm. Within each subarray, 256 spots were printed at known locations, containing 40 different features (antibodies for specific antigens) in quadruplicate (160 spots). The remaining features comprised of controls for antibody immobilization, Cy5-labeled mouse IgG and internal calibrators (biotin mouse IgG).

*RCA microarray immunoassays.* Slides were blocked by adding 30 *μ*L blocking buffer (0.5% nonfat dry milk, 0.2% BSA, and 0.05% Tween-20 in PBS) to each subarray and incubating for 1 hour at 37°C in a humidified chamber, and then washed by immersion in PBS containing 0.5% Brij 35 for 2 minutes. A 15 *μ*L aliquot of sample (single analyte or mixture of multiple analytes; serum, plasma, or culture supernatant) was immediately added to each subarray, incubated for 30 minutes at 37°C, and then washed as described above. After analytes were captured, a 20 *μ*L aliquot of the appropriate mixture of biotinylated detection antibodies at 0.1 *μ*g/mL each was applied to individual arrays and incubated at 37°C for 30 minutes in a humidified chamber. Slides were washed twice for two minutes in PBS containing 0.5% Brij 35. A mouse monoclonal antibiotin antibody-primer conjugate was prepared by derivatization of a mouse monoclonal antibiotin IgG (Jackson ImmunoResearch Laboratories, Inc, West Grove, Pa) with a 5\'-terminal amine-modified oligonucleotide primer, 5\'-Thiol-AAA AAA AAA AAA AAA CAC AGC TGA GGA TAG GAC AT-3\', as previously described \[[@B9]\]. The conjugate was annealed with 75 nM circle 1 (cyclic 5\'-CTC AGC TGT GTA ACA ACA TGA AGA TTG TAG GTC AGA ACT CAC CTG TTA GAA ACT GTG AAG ATC GCT TAT TAT GTC CTA TC-3\') in PBS containing 0.05% Tween-20 and 1 mM EDTA at 37°C for 30 minutes. Twenty microliters of the conjugate-circle mixture was applied to each array. Slides were incubated at 37°C for 30 minutes and then washed twice. RCA reaction mixture (20 *μ*L) containing native T7 DNA polymerase (20 U/mL), 1 mM dNTPs, ssDNA-binding protein 22 *μ*g/mL, 1x sequenase buffer, 8% DMSO, and 0.05 mM Cy5 decorator (5\'-Cy5-TGT CCT ATC CTC AGC TGG-Cy5) was added to each subarray. Slides were incubated at 37°C for 45 minutes, then washed twice in PBS containing 0.5% Brij 35 and once in PBS, and spin-dried. Arrays were analyzed on an Axon *GenePix 4000B* scanner (Axon Instruments Inc, Foster City, Calif), and fluorescence quantitated by using GenePix Pro 3.0 quantitation software. Data was analyzed by using MSI Analyzer software (Molecular Staging, Inc).

![Schematic representation of microarray immunoassay with RCA signal amplification. It consists of (a) analyte capture by antibody immobilized on microarray, (b) detection by biotinylated secondary antibody, (c) binding of antibiotin antibody-oligonucleotide conjugate pre-annealed with circle 1, and (d) rolling-circle replication to generate long single-strand DNA which is hybridized with oligonucleotide decorator.](20926.fig.001){#F1}

RESULTS AND DISCUSSION
======================

Fabrication of antibody microarray
----------------------------------

Microarrays were printed on cyanosilane-coated glass slides. This surface was chosen based on experiments indicating that cyanosilane-activated slides have the advantages of (1) simpler preparation, (2) less-expensive reagents, and (3) more uniformity of bound antibody spot morphology over thiolsilane-coated and cross-linker (such as GMBS) activated glass slides (data not shown). The concentration of capture antibody for printing was optimized by comparing specific signal intensities from the same capture antibody printed on the chip at different concentrations chosen for microarray printing. Specific signals at 0.5 mg/mL reached the point of saturation (data not shown), indicating that antibodies saturated the area available for immobilization in the spot. The uniformity of antibody immobilization on the chip was assessed by measuring the coefficient of variation (CV) from the quadruplicate spots using Cy5-labeled anti-isotype antibodies (against the species used in the capture antibodies), previously reported as approximately 10% for each feature on the chip\[[@B4]\].

Improving the sensitivity of protein detection on antibody array
----------------------------------------------------------------

Rolling circle amplification enables amplification of signals tethered to proteins and nucleic acids \[[@B4], [@B9], [@B11]\]. Immunoassays incorporating RCA have shown a large increase in sensitivity when compared with the direct assay \[[@B4]\]. The technique consists of protein capture by antibody immobilized on microarrays, detection by biotin-labeled second antibody specific for the captured protein, binding of a universal antibiotin antibody oligonucleotide conjugate pre-annealed with circle, and RCA signal amplification where a long single-strand DNA is generated by rolling-circle replication in the presence of DNA polymerase and nucleotides, with hybridization of the RCA product to fluorescent-labeled complementary oligonucleotide probes occurring simultaneously ([Figure 1](#F1){ref-type="fig"}). Besides the signal amplification by RCA, the sensitivity of the antibody array was further improved by two approaches: (1) choosing optimal capture and detection antibody pairs for the microarray immunoassay and (2) optimizing assay procedures.

###### 

Optimization of antibodies from different sources (A and B) for choosing optimal pair for immunoassay on protein microarray with examples of (a) IL-13 and (b) MCP-2.
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Antibody microarray development commenced with selection of optimal antibody pairs. For individual features, if the matched antibody pair developed for conventional ELISA was available, it was preferentially selected for the chip development. However, in terms of sensitivity and specificity, antibody pairs do not always function equivalently on plastic ELISA plates and the glass-based microarrays. Antibody pairs from different manufacturers for the same antigen with similar sensitivity as ELISA assays perform quite differently in microarrays. Thus it has become necessary to select optimal pairs for antibody microarrays by comparing all available antibodies and pairs. As an example, [Figure 2](#F2){ref-type="fig"}a shows the difference between two matched pairs of antibodies (for ELISA) from different sources with specificity for detecting the cytokine IL-13 using the antibody microarray. The pair from source A showed strong signal intensity with a sensitivity of less than 100 pg/mL. However, the pair from source B did not show signal even at concentrations as high as 5 ng/mL IL-13. Selecting the antibody pair from source A provided at least 50-fold increase of sensitivity when compared with the pair from source B. Alternatively, the ELISA antibody pair from the same set is not always the optimal for a microarray immunoassay. One example shown in [Figure 2](#F2){ref-type="fig"}b is for the chemokine MCP-2. Neither of the ELISA-matched pairs showed sensitivity better than 100 pg/mL on the microarray slides. However, using a capture antibody from A and a detection antibody from B, the sensitivity for MCP-2 was improved to 10 pg/mL or better, a 10-fold increase in sensitivity relative to a single manufacturer\'s reagents. For features without matched pairs, monoclonal antibodies with different binding epitopes or polyclonal antibodies were extensively evaluated for sensitivity ranges permitting detection of biologically relevant changes in protein expression. Cross-reactivity and nonspecific signals were also extensively evaluated as described below.

![Titration of SSB in the RCA reaction mixtures. Cytokine IL-8 and Eot-2 at 100 pg/mL were detected.](20926.fig.003){#F3}

###### 

Performance characteristics of the 150-feature protein microarray.

  -------------- --------------------------- --------------------------- --------------------------- ---------------------------
  Analyte        Biological ED~50~ (pg/mL)   Mean serum levels (pg/mL)   Array sensitivity (pg/mL)   ELISA sensitivity (pg/mL)
                                                                                                     
  ALCAM          na                          52 000                      100                         24
  ANG            na                          360 000                     10                          6
  AR             5000--15 000                45.4                        100                         na
  BDNF           3000--10 000                27 793                      10                          20
  BLC            5000--20 000                na                          10                          na
  SVE-cadherin   na                          2800                        1000                        313
  CCL28          400 000--2 000 000          43.8                        30                          2.58
  SCD23          na                          1.3 IU/mL                   10 000                      0.15 U/mL
  CD27           na                          na                          100                         na
  CD30           30 000--100 000             6.4 U/mL                    10                          na
  CD40           na                          102.1                       300                         15.6
  CNTF           50 000--150 000             nd                          300                         8
  CNTF R*α*      200 000--400 000            na                          100                         na
  CT-1           1000--4000                  619.5                       1000                        na
  CTACK          100 000--400 000            522                         10                          1.55
  CTLA-4         2 000 000--4 000 000        nd                          1000                        313
  DR6            na                          na                          10                          na
  EGF            100--400                    336                         10                          0.7
  ENA-78         3000--15 000                1449                        100                         15
  Eot            10 000--20 000              68.6                        10                          5
  Eot-2          10 000--50 000              249                         10                          1.83
  Eot-3          250 000--1 000 000          9.7                         100                         2
  Fas            10 000--40 000              9406                        100                         20
  Fas ligand     200 000--500 000            nd                          100                         100
  FGF acidic     100 000--300 000            na                          10                          na
  FGF basic      100 000--250 000            nd                          100                         3
  FGF-4          50--150                     93.8                        300                         30
  FGF-6          100--300                    na                          100                         na
  FGF-7          15 000--25 000              \< 31.2                     10                          15
  FGF-9          1000--2000                  na                          100                         na
  Flt-3 L        500--1000                   93.9                        10                          7
  Follistatin    100 000--400 000            2483                        30                          29
  G-CSF          20--60                      22                          1000                        20
  GCP-2          na                          156                         100                         1.6
  GDNF           1000--3000                  na                          10                          na
  GM-CSF         20--80                      1.72                        10                          3
  Sgp130         3000--9000                  306 000                     100                         80
  GRO-*α*        1000--4000                  93                          10                          10
  GRO-*β*        3000--300 000               na                          10                          na
  GRO-*γ*        10 000--100 000             na                          10                          na
  HB-EGF         2000--5000                  na                          100                         na
  HCC-1          200 000--8 000 000          na                          30                          na
  HCC4           150 000--750 000            na                          100                         na
  HGF            20 000--40 000              721                         100                         40
  HVEM           500 000--2 000 000          na                          30                          na
  ICAM-1         na                          211 000                     10                          350
  ICAM-3         na                          50 000                      100                         580
  IFN-*α*        3.8×10^8^ U/mg              \< 10                       100                         15.6
  IFN-*γ*        800--1500                   \< 15.6                     10                          8
  IFN-*ω*        na                          nd                          100                         9.375
  IGF-I          1000--3000                  105 000                     100                         26
  IGF-IR         na                          na                          100                         na
  IGF-II         5000--10 000                29 300                      1000                        na
  IGFBP-1        1 000 000--4000 000         14 300                      30                          na
  IGFBP-2        30 000--90 000              434 200                     100                         na
  IGFBP-3        50 000--150 000             2 375 000                   1000                        50
  IGFBP-4        30 000--90 000              na                          100                         na
  I-309          3000--9000                  nd                          10                          0.71
  IL-1*α*        3.0--7.0                    \< 3.9                      10                          1
  IL-1*β*        13--20                      0.536                       10                          1
  IL-1r*α*       20 000--60 000              418                         100                         22
  IL-1 sRI       500 000--1000 000           na                          100                         na
  IL-1 sRII      1 000 000--5000 000         11 000                      10                          10
  IL-2           250--500                    1.6                         10                          7
  IL-2 R*β*      1 000 000--3000 000         na                          300                         na
  IL-2 sRa       500 000--1 000 000          1346                        10                          10
  IL-2 R*γ*      3 000 000--6 000 000        na                          30                          na
  IL-3           100--400                    \< 31.2                     1000                        7.4
  IL-4           50--200                     \< 0.25                     10                          10
  IL-5           100--200                    \< 7.8                      10                          3
  IL-5 R*α*      200 000--300 000            na                          100                         na
  IL-6           200--800                    1.62                        10                          0.7
  IL-6 sR        5000--15 000                31 000                      10                          7
  IL-7           200--500                    2.82                        10                          0.1
  IL-8           100--500                    13.2                        1                           10
  IL-9           500--1000                   na                          1000                        na
  IL-10          500--1000                   2                           10                          3.9
  IL-10 R*β*     na                          na                          10                          na
  IL-11          60--240                     \< 31.2                     100                         8
  IL-12 (p40)    50--200                     77                          10                          15
  IL-12 (p70)    50--200                     1.93                        10                          0.5
  IL-13          3000--6000                  \< 62.5                     10                          32
  IL-15          500--2000                   2.14                        100                         2
  IL-16          2 000 000--10000 000        171                         100                         6.2
  IL-17          2000--6000                  \< 31.2                     10                          15
  IL-18          na                          126                         100                         12.5
  IL-21          10 000--40 000              na                          300                         na
  IP-10          20 000--60 000              89                          10                          1.7
  I-TAC          1000--5000                  177                         10                          13.9
  Leptin/OB      400--2000                   4760(M), 20676(F)           3000                        7.8
  LIF            500                         na                          100                         8
  SLIF-R*α*      3 000 000--6000 000         4300                        300                         156
  Lymphotactin   50 000--200 000             na                          100                         na
  M-CSF          500--1500                   670                         10                          9
  M-CSF R        4000--12 000                na                          300                         na
  MCP-1          5000--20 000                370                         10                          5
  MCP-2          30 000--120 000             200                         10                          na
  MCP-3          20 000--80 000              \< 15.6                     10                          2
  MCP-4          200 000--400 000            na                          300                         na
  MDC            3000--9000                  1089                        10                          62.5
  MIF            50 000--100 000             1337                        100                         na
  MIG            200 000--600 000            914                         10                          na
  MIP-1*α*       2000--10 000                \< 46.9                     10                          10
  MIP-1*β*       10 000--30 000              80                          10                          11
  MIP-1*δ*       2000--4000                  na                          100                         na
  MIP-3*α*       500--2000                   26.3                        30                          0.47
  MIP-3*β*       100 000--300 000            na                          10                          na
  MMP-1          na                          6490                        300                         52
  MMP-2          na                          1 169 000                   300                         na
  MMP-7          na                          2290                        100                         16
  MMP-9          na                          436 000                     300                         156
  MMP-10         na                          770                         100                         4.13
  MPIF           200 000--500 000            536                         100                         3.3
  MSP            10 000--30 000              4 nM                        100                         na
  NAP-2          100 000--300 000            na                          100                         na
  *β*-NGF        800--1500                   265                         10                          na
  NT-3           10 000--30 000              13.4                        100                         na
  NT-4           5000--15 000                na                          10                          na
  OSM            150--300                    \< 15.6                     10                          na
  PARC           500 000--2000 000           na                          100                         na
  PDGF-R*α*      5 000 000--10 000 000       na                          3000                        na
  PECAM-1        na                          20 000                      1000                        na
  PF4            5 000 000--15 000 000       14 700                      300                         na
  PlGF           na                          18                          10                          7
  Prolactin      30--100                     9300                        1000                        7.6 mIU/L
  RANK           4000--10 000                na                          300                         na
  RANTES         1000--5000                  49 137                      10                          8
  SCF            2 500--5000                 984                         10                          9
  SCF R          2 000 000--6000 000         na                          100                         na
  SDF-1*α*       3000--9000                  2000                        10 000                      18
  SDF-1*β*       10 000--30 000              na                          10 000                      na
  L-Selectin     na                          954 000                     10                          300
  ST2            na                          500                         30                          na
  TARC           3000--9000                  331                         100                         5
  TGF-*α*        100--400                    22                          100                         na
  TGF-*β*1       20--60                      48 600                      10                          7
  TGF-*β*3       10.0--30.0                  2400                        10                          na
  TIMP-1         8 nM                        190 000                     30                          80
  TIMP-2         na                          106 000                     10                          na
  TNF-*α*        20--50                      1.25                        3                           4.4
  TNF-*β*        20--50                      \< 156                      10                          16
  TNF RI         45 000--90 000              1198                        10                          3
  TNF-RII        4000--16 000                1725                        100                         1
  TRAIL          4000--12 000                nd                          5000                        120
  TRAIL R1       1000--3000                  na                          10                          na
  TRAIL R4       30 000--60 000              na                          100                         na
  UPAR           50 000--150 000             2370                        100                         33
  SVAP-1         na                          125 900                     100                         300
  VEGF           2000--6000                  220                         10                          9
  VEGF-R2        4000--8000                  9768                        1000                        4.6
  -------------- --------------------------- --------------------------- --------------------------- ---------------------------

###### 

Cross-reactivity of capture antibodies and analytes ((a) and (c)), capture antibodies and detection antibodies ((b) and (d)) on the subarrays 3 (A) and 4 (B). Each subarray was printed with about 35 different capture antibodies (listed on the chart). Cross-reactivity was determined by using different matched secondary antibody and 50 ng/mL or 0 ng/mL of its cognate analyte, which has been described in the text. A shaded square off the diagonal indicates the presence of nonspecific signals (intensity ≥ 300). None of these nonspecific signals exceed the intensity of 600 fluorescence intensity units (images are scanned at PMT of 600 and power of 100% on Axon scanner).
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###### 

Protein expression profiling of normal human serum (Sigma) on 70-feature antibody microarray. Specific signals detected were consistent with the protein level in serum. (a) Images of detecting 70 proteins in antibody microarray obtained with Axon microarray scanner. (b) Fluorescence intensities were derived from microarray images with averaging four spots of the same feature.
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The second approach of improving sensitivity was to optimize the assay procedures. This involved optimizing detection antibody concentrations, conjugate and circle concentrations, incubation temperatures and time, and RCA reaction solution composition. Analogous to sandwich ELISA assays, the conditions giving the best signal to noise ratio were found to be 0.1 *μ*g/mL of detector with assay incubation time of 30 minutes at 37°C. Titration of conjugate and circle pre-annealed to conjugate revealed the optimal concentration to be 2 *μ*g/mL conjugate with 75 nM circle. Other components, such as the concentration of single-strand DNA binding protein (SSB), were also optimized for maximum sensitivity in RCA reaction mixtures ([Figure 3](#F3){ref-type="fig"}).

The analytical sensitivity of the microarray immunoassay was determined by using serial dilutions of each single purified antigen. The sensitivity of detection, defined as the lowest concentration that delivered clear specific signal intensity above detection threshold (mean intensity of the negative control plus 2 SD), was calculated. Sixty-five (43%) of the 150 cytokine features had a sensitivity of ≤ 10 pg/mL, 52 (35%) had a sensitivity of ≤ 100 pg/mL, 27 (18%) had a sensitivity of ≤ 1000 pg/mL, and 6 (4%) had a sensitivity of ≥ 1,000 pg/mL ([Table 1](#T1){ref-type="table"}). Sixty-two of the cytokines represented on the chip are unique, with no corresponding commercially available ELISA kits. The sensitivity goal for these arrays was adequacy to detect biologically relevant (ie, 2-fold) increases in cytokine level above normal values in clinical fluids including serum and plasma.

Specificity of antibody microarray
----------------------------------

Although antibodies are highly specific for their respective cognate proteins, it is possible that structurally related proteins might have similar epitopes. Cross-reactivity or nonspecific signals between immobilized capture antibodies and antigens or detection antibodies for 150 features were determined in three different ways. First, the cross-reactivity of individual antigens or detection antibodies was determined by analyzing a single antigen at 0 and 50 ng/mL with its corresponding paired detection antibody. Any signals on the 0 ng/mL array were categorized as cross-reactivity between the detection and capture antibodies. With 50 ng/mL analyte, signals should have only been observed at the specific locations. Other signals after background subtraction (the 0 ng/mL array) were assumed to be cross-reactivity from the analyte. Nonspecific signals were eliminated by segregating all features into multiple subarrays, thus the capture antibodies producing nonspecific signals were physically separated from those particular detection antibodies or antigens. This also allowed simultaneous detection of both components of a biological signaling system, such as a growth factor and its receptor.

Residual cross-reactivity and nonspecific signals were first minimized by optimization of washing and blocking conditions \[[@B4]\]. Next, a mixture of several analytes at concentrations of 10 ng/mL each was applied to the chip, followed by detection with the complete detection antibody cocktail. Signals were only observed where both the analyte and its specific detection antibody were present. Then a mixture of all analytes in the subarray at 10 ng/mL each was added to the microarray, but detection was with an incomplete cocktail of antibodies. Signals were only detected on those features corresponding to the specific detection antibodies added. As shown in [Figure 4](#F4){ref-type="fig"}, both cross-reactivity between capture antibodies and analytes and cross-reactivity between capture antibodies and detection antibodies in each subarray were minimized. Approximately 99% of nonspecific binding pairs had fluorescence intensity units of less than 300, used as the background signal minimum during the data quantitation. Interferences from biological specimen were screened using normal human serum and single detectors (biotinylated detection antibody) corresponding to each feature on the chip. Only specific signals of the proteins present in the specimen were detected by their associated detector antibody. Other nonspecific signals or background signals were negligible.

Validation of the antibody microarray
-------------------------------------

The antibody microarray was validated by running assays with normal human serum (Sigma, St. Louis, Mo) on our 70-feature protein chip. We simultaneously detected 70 proteins in normal human serum. Signals corresponding to specific proteins were identified ([Figure 5](#F5){ref-type="fig"}), which are consistent with their presence with significant level in the normal human serum ([Table 1](#T1){ref-type="table"}). Proteins with low fluorescence signal intensities agree with their very low level in serum (if present), indicating that our antibody microarray provides a specific, robust, and high-throughput approach for global analysis of protein expression.

CONCLUSION
==========

Immunoassays on microarrays hold appeal for studies requiring the ability to quantify many selected proteins simultaneously. Considerable progress has been made in this area recently in terms of increased assay sensitivity and complexity (ie, degree of multiplexing). Rolling-circle amplification facilitates the use of such arrays with its powerful degree of signal enhancement and simultaneous detection of a large number of defined analytes. Such robust systems will enable routine use of antibody arrays in both research and diagnostic modalities.
